Tildy, Bernadett E. http://orcid.org/0000-0002-8033-470X
McNeill, Ann
Robins, John
Dregan, Alexandru
Richardson, Sol
Brose, Leonie S.
Funding for this research was provided by:
Economic and Social Research Council (LISS DTP es/p000703/1)
United Kingdom Prevention Research Partnership (MR/S037519/1, MR/S037519/1, MR/S037519/1)
National Institute for Health Research Applied Research Collaboration South London
Article History
Received: 31 August 2023
Accepted: 9 November 2023
First Online: 16 November 2023
Declarations
:
: CPRD research data services are delivered by the Medicines and Healthcare products Regulatory Agency (MHRA) with support from the National Institute for Health and Care Research (NIHR), as part of the Department of Health and Social Care. CPRD collects anonymised patient data from a network of GP practices across the UK. Primary care data are linked to a range of other health related data to provide a comprehensive longitudinal, representative UK population health dataset. CPRD has ethical approval from the Health Research Authority (HRA) to support research using anonymised patient data, reference: East Midlands - Derby Research Ethics Committee (REC): 21/EM/0265. For more information see: ExternalRef removed and ExternalRef removed and ExternalRef removed.In order for researchers to access CPRD data, researchers complete a study protocol which is reviewed via CPRD’s Research Data Governance (RDG) Process. (The RDG process was formerly called the ISAC.) Independent scientific and patient advice is provided by Expert Review Committees (ERCs) and the Central Advisory Committee (CAC). The RDG process ensures that investigators using CPRD data for research have viable plans that maintain public and professional trust, ensure the research is of public benefit, and are methodologically robust. Informed consent from individual patients included in research studies is not gained by individual investigators because the data that CPRD manages is anonymised.This study protocol was granted scientific and ethical approval by this process; the Medicine and Healthcare Regulatory Agency (MHRA) Independent Scientific Advisory Committee (ISAC: Protocol No. 21_000706).
: Not applicable.
: The authors declare no competing interests.